Organon & Co.

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

OGN$13.85-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

($ in millions except shares in thousands and per share amounts)

	December 31, 2024	December 31, 2023
Assets
Current Assets:
Cash and cash equivalents	$675	$693
Accounts receivable (net of allowance for doubtful accounts of $14 in 2024 and $9 in 2023)	1,358	1,744
Inventories (excludes inventories of $215 in 2024 and $110 in 2023 classified in Other assets)	1,321	1,315
Other current assets	994	756
Total Current Assets	4,348	4,508
Property, plant and equipment, net	1,168	1,183
Goodwill	4,680	4,603
Intangibles, net	1,414	533
Other assets	1,491	1,231
Total Assets	$13,101	$12,058
Liabilities and Equity
Current Liabilities:
Current portion of long-term debt	$20	$9
Trade accounts payable	1,153	1,314
Accrued and other current liabilities	1,411	1,389
Income taxes payable	134	206
Total Current Liabilities	2,718	2,918
Long-term debt	8,860	8,751
Deferred income taxes	74	47
Other noncurrent liabilities	977	412
Total Liabilities	12,629	12,128
Contingencies (Note 18)
Organon & Co. Stockholders’ Equity (Deficit):
Common stock, $0.01 par valueAuthorized - 500,000Issued and outstanding - 257,799 in 2024 and 255,626 in 2023	3	3
Additional paid-in capital	108	25
Retained earnings	1,010	443
Accumulated other comprehensive loss	(649)	(541)
Total Stockholders’ Equity (Deficit)	472	(70)
Total Liabilities and Stockholders’ Equity (Deficit)	$13,101	$12,058

-59-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.